Individual License: $2,950 | Team and Enterprise License Options Available

Latin America’s Oncology Imaging AI market is forecast to grow from US$46.8M in 2023 to US$340.0M by 2032 (24.7% CAGR)—a smaller base than North America/Europe/APAC, but a meaningful decade of compounding driven by screening throughput needs, constrained specialist capacity, and expanding cloud-first deployment models.

Overview

Latin America Oncology Imaging AI Pulse 2025–2032 is Marketstrat’s regional market sizing and forecasting report focused specifically on AI in cancer imaging across LATAM. It delivers a decision-grade view of market size, growth, and mix shifts across the core segmentation axes that matter for strategy and GTM:

• Modality: CT; X‑ray/DR (including mammography/DBT); MRI; PET/Nuclear; ultrasound
• Tumor site: breast, lung/chest, prostate, colorectal, liver, neuro-oncology, gynecologic, head & neck, other/rare
• Care pathway stage: screening/risk; detection/diagnosis; staging; treatment planning (including RT); response assessment; surveillance/follow-up
• Clinical application: detection/diagnosis; quantification/analytics; workflow/orchestration; reporting/communication; reconstruction/acquisition
• Revenue streams: hardware; software; services; cloud/usage-based (PPU)
• End-use settings: academic/IDN environments, cancer centers, community providers, and teleradiology networks

This Pulse is designed for executives who need a clean LATAM-specific market view for commercial planning, product sequencing, partnership strategy, and investment screening—without requiring a full global Horizon package.

Market Snapshot

• Market size (LATAM): US$46.8M (2023) → US$340.0M (2032)
• Growth rate: 24.7% CAGR (2023–2032)
• What drives the market mix: LATAM remains front-of-pathway weighted, with a large share of spending concentrated in screening and diagnostic workflows, where AI improves throughput, standardization, and quality assurance.
• Where the dollars concentrate: The largest value pools are typically anchored in CT and X‑ray/DR (including mammography/DBT), with MRI rising as a premium quantification and staging platform and PET/Nuclear growing as a high-value niche in advanced oncology programs.
• How monetization shifts: Software remains the primary revenue engine, while cloud/usage-based (PPU) models expand materially by 2032—especially where adoption is driven by centralized reading, multi-site networks, and constrained radiologist supply.

Key Market Trends (LATAM)

1. Cloud-first economics accelerate adoption
   LATAM adoption patterns increasingly favor lower-friction deployment—cloud delivery, usage-based pricing, and platform distribution—especially when capex budgets are constrained and time-to-value matters.
2. Screening and high-volume workflows define near-term ROI
   Breast and lung pathways anchor predictable volumes, making triage, QA, and workflow integration as commercially important as algorithm performance.
3. From detection to measurement: quantification becomes the expansion layer
   As foundational detection tools become more common, growth shifts toward measurement-grade outputs—quantification, structured reporting, longitudinal tracking, and response workflows.
4. Services become a differentiator, not an add-on
   Implementation support (integration, workflow redesign, training, monitoring) is often essential to scaling beyond pilots—especially in heterogeneous provider environments.
5. Teleradiology and hub models expand the addressable market
   Centralized reading networks can standardize protocols and spread AI benefits across multiple sites, supporting adoption in areas with specialist scarcity.

Commercial Snapshot

This Pulse focuses on how the LATAM market is captured—not vendor market shares. Key commercial realities include:

• Distribution and workflow fit often matter as much as “best-in-class” accuracy
• Platform and marketplace models reduce integration burden for multi-site deployments
• Usage-based pricing expands in screening and centralized reading environments
• Implementation services (validation, training, monitoring) influence renewals and expansion more than in mature markets

Sample Insights & Figures

Readers can use this report to answer questions such as:

• Which modalities are the largest pools versus the fastest-growing pools in LATAM?
• How does LATAM’s mix by pathway stage compare to global patterns (screening/detection vs downstream monetization)?
• Where does cloud/PPU monetization expand fastest—and what does that imply for GTM packaging?
• Which tumor sites (e.g., breast, lung/chest, prostate) concentrate the majority of regional opportunity?

What’s Inside

• A LATAM-focused Executive Summary with key forecast headlines and mix shifts
• A condensed methodology tailored to this regional Pulse scope
• Full LATAM market sizing and forecasts (2023–2032) across modality, tumor site, pathway stage, clinical application, end-use, and revenue stream
• “Mix & momentum” style tables/figures that show where spending concentrates and where incremental dollars accrue

Why This Report

Latin America is often underserved by generic global AI narratives. This Pulse provides a LATAM-specific quantitative baseline to support real decisions:

• Market prioritization: where to focus first (high-volume anchors) vs where to place selective premium bets (MRI/PET expansion)
• Product sequencing: detection/workflow entry → quantification/analytics expansion → longitudinal and response layers
• GTM design: channel strategy, platform partnerships, and monetization structure (license vs usage vs services)
• Investment and diligence: sanity-check growth claims using segmentation-consistent forecasts rather than anecdotal signals

Report Stats

• No. of Pages: 35
• No. of Figures: 14
• No. of Tables: 7
• Price: Individual License: $2,950 | Team License: $3,450 | Enterprise License $3,950
• SKU: MINTP-M01119-6